# Phase 1b of ASLAN001 (Varlitinib) in Patients With Advanced/ Metastatic Hepatocellular Carcinoma (HCC)

> **NCT03499626** · PHASE1,PHASE2 · UNKNOWN · sponsor: **National University Hospital, Singapore** · enrollment: 22 (estimated)

## Conditions studied

- Advanced/ Metastatic Hepatocellular Carcinoma

## Interventions

- **DRUG:** ASLAN001

## Key facts

- **NCT ID:** NCT03499626
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-05-05
- **Primary completion:** 2019-05-05
- **Final completion:** 2021-05-05
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2018-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03499626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03499626, "Phase 1b of ASLAN001 (Varlitinib) in Patients With Advanced/ Metastatic Hepatocellular Carcinoma (HCC)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03499626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*